Tymlos (Abaloparatide) Legal and Patent Challenges: What Women With Osteoporosis Need to Know

What Is Tymlos and Why Does Its Regulatory History Matter to You?

Tymlos is a synthetic analog of parathyroid hormone-related protein (PTHrP) that builds bone rather than just slowing its loss. It was developed specifically for postmenopausal women, who account for roughly 80 percent of the 10 million Americans living with osteoporosis. The drug's regulatory and patent timeline directly affects whether you can access it, what it costs, and how safe the current labeled version is considered to be.

Patent challenges and FDA label changes are not just legal footnotes. They determine whether a lower-cost biosimilar or generic ever reaches the market, how long Radius Health can keep exclusive pricing, and what updated warnings your prescribing clinician must discuss with you.

The Core Problem With Bone Loss in Postmenopausal Women

Estrogen withdrawal at menopause accelerates bone resorption. In the first five to seven years after the final menstrual period, women may lose up to 20 percent of bone density. Antiresorptive agents (bisphosphonates, denosumab) slow that loss, but anabolic agents like abaloparatide and teriparatide actually stimulate new bone formation, making them the preferred option for women with very high fracture risk, multiple prior fractures, or failure of antiresorptive therapy according to ACOG guidance on osteoporosis management.

How Abaloparatide Differs From Teriparatide

Abaloparatide preferentially binds the RG conformation of the PTH1 receptor, which drives bone formation with less receptor internalization than teriparatide. In practical terms, the ACTIVE trial published in JAMA in 2016 showed that over 18 months in 2,463 postmenopausal women, abaloparatide reduced new vertebral fractures by 86 percent relative to placebo (0.58% vs. 4.22%, p <0.001) and reduced nonvertebral fractures by 43 percent relative to placebo (p=0.049). These are the numbers that earned FDA approval in 2017.

FDA Approval: The Timeline and Label History

April 2017: Initial Approval

The FDA approved Tymlos on April 28, 2017 under NDA 208743 for the treatment of postmenopausal women with osteoporosis at high risk of fracture. The approval was supported by the ACTIVE trial and an open-label extension study (ACTIVExtend) that tracked participants who rolled over from abaloparatide to alendronate.

2019 Label Revision: Cardiovascular and Hypercalcemia Warnings

Post-market surveillance identified a small but statistically meaningful increase in atrial fibrillation events in the ACTIVE trial (1.7% abaloparatide vs. 0.7% placebo). The FDA required a label update in 2019 that added cardiovascular precautions and strengthened the warning about hypercalcemia and hypercalciuria. If you have a history of cardiac arrhythmia, your clinician should review this section of the prescribing information with you before starting Tymlos.

2021: Subcutaneous Patch (Abaloparatide-SC) Receives Its Own NDA

Radius Health filed a separate NDA for a transdermal abaloparatide micropatch (abaloparatide-SC, brand name Tymlos Patch) in 2021. The FDA issued a Complete Response Letter (CRL) requesting additional manufacturing data. As of early 2025, the patch formulation has not received approval. This is worth tracking because a patch could improve adherence for women who find daily self-injection difficult.

2022: Label Expansion to Adult Men

The FDA approved a supplemental NDA extending the Tymlos indication to adult men with osteoporosis at high fracture risk or who have failed other therapies. The bone biology and dosing are the same, but the clinical evidence base in women remains far more extensive. Women's data from the ACTIVE trial drove the original label; male data are extrapolated from smaller pharmacodynamic studies, which is an evidence gap worth naming plainly.

Patent Field and Legal Challenges

What Patents Does Radius Hold on Tymlos?

Radius listed multiple patents in the FDA Orange Book for abaloparatide. These cover the compound itself (composition of matter), the formulation used in the prefilled pen, and methods of treating osteoporosis with the specific dosing regimen. Composition-of-matter patents typically offer the strongest exclusivity because they block any manufacturer from making the molecule, not just copying a specific formulation.

Paragraph IV Certifications and Generic Challenges

Under the Hatch-Waxman Act, a generic applicant that believes a listed patent is invalid or would not be infringed files a Paragraph IV certification. Paragraph IV filings trigger a 30-month regulatory stay that prevents FDA from approving the generic application while litigation proceeds, unless a court rules earlier.

Multiple generic manufacturers filed Paragraph IV ANDAs against Tymlos patents beginning in 2021. Radius sued each filer within the 45-day window required to trigger the automatic 30-month stay. As of early 2025, those cases remain unresolved in U.S. District Court. Because the litigation is ongoing and court filings are sealed in part, the specific patent claims at issue are not fully public. What is public is that no generic abaloparatide has received FDA approval, meaning the branded Tymlos pen remains the only option.

What the Patent Battle Means for Your Wallet

Without generic competition, Tymlos carries a list price of approximately $2,200 to $2,400 per month. Many commercial insurance plans cover it under specialty tier with significant cost-sharing. The Radius patient assistance program (EMBRACE) can reduce out-of-pocket costs for eligible patients, but eligibility criteria and income thresholds change annually.

If and when a generic clears litigation and receives FDA approval, prices could fall substantially, as has happened with other specialty injectables after patent expiry.

Biosimilar vs. Generic: Why the Distinction Matters for a Peptide Drug

Abaloparatide is a 34-amino-acid synthetic peptide. Technically it falls into a regulatory gray zone: it is complex enough that the FDA could require an abbreviated biologic pathway (351(k) biosimilar) rather than a standard small-molecule ANDA. FDA guidance on peptide drug classification published in 2021 clarified that peptides approved before March 23, 2020 under NDAs retain that NDA status, meaning generic ANDAs (not biosimilar applications) apply. This distinction favors generic manufacturers because ANDA requirements are less burdensome than biosimilar BLA requirements.

Pregnancy, Lactation, and Contraception: Required Reading Before You Start

Tymlos is contraindicated in pregnancy. This is not a relative caution; it is a hard stop.

Animal Data and the Evidence Gap in Humans

No controlled studies of abaloparatide have been conducted in pregnant women, and none will be, given the drug's mechanism and animal findings. In rat studies, abaloparatide at doses approximately 28 times the recommended human dose caused fetal skeletal malformations. There are no adequate human data.

The Tymlos label assigns no traditional pregnancy category (the old A/B/C/D/X system was phased out in 2015), but the prescribing information plainly states that the drug may cause fetal harm based on animal data and advises women of reproductive potential to use effective contraception during treatment.

Who Is at Risk? A Life-Stage Reality Check

Tymlos is approved for postmenopausal women, so most users are past reproductive years. But several scenarios create real pregnancy risk:

• Perimenopausal women who are told they are "probably infertile" but have not had 12 consecutive months without a period may still ovulate sporadically. Pregnancy is documented in perimenopause.
• Premenopausal women with secondary osteoporosis from conditions like anorexia nervosa, premature ovarian insufficiency (POI) treated with hormone therapy, or long-term glucocorticoid use may have bone loss severe enough that an anabolic agent is considered. Abaloparatide is not FDA-approved in this population, but off-label use does occur.
• Women who experience menopause reversal (extremely rare spontaneous follicular activity) have been documented in case reports.

If there is any possibility you could become pregnant, reliable contraception is required during Tymlos treatment. Discuss this explicitly with your prescriber before your first injection.

Lactation

There are no data on abaloparatide transfer into human breast milk, the effects on a breastfed infant, or the effects on milk production. Given that Tymlos is approved for postmenopausal women, lactation is not a typical concern, but any woman in an unusual clinical situation should ask her clinician directly before starting the drug. The safest clinical position is to avoid Tymlos while breastfeeding until human lactation data exist.

Contraception Requirements

For any woman who retains reproductive potential and is considered for Tymlos (on-label or off-label), a highly effective contraceptive method should be in place before starting and maintained throughout the full treatment course. Options compatible with bone health in women with hypoestrogenic states include combined oral contraceptives, hormonal IUDs, or progestin-only pills, though the estrogen component of combined pills may independently benefit bone density in premenopausal women. Discuss the best fit for your hormonal history with your provider.

Tymlos Safety Profile: What the Label and Post-Market Data Say

Most Common Side Effects

The current Tymlos prescribing information lists the following adverse reactions occurring in at least 2 percent of patients in the ACTIVE trial and more often than placebo:

| Adverse Reaction | Abaloparatide (%) | Placebo (%) | |---|---|---| | Hypercalciuria | 11.3 | 9.0 | | Dizziness | 10.0 | 6.5 | | Nausea | 8.1 | 5.2 | | Headache | 8.1 | 6.3 | | Palpitations | 6.8 | 3.9 | | Fatigue | 3.0 | 2.7 | | Injection site reactions | 58.1 | 28.0 |

Injection site reactions (pain, erythema, bruising) are the most frequent complaint in clinical practice. Rotating injection sites on the abdomen and ensuring the pen is at room temperature before injecting both reduce local reactions.

Hypercalcemia and Kidney Stones

Abaloparatide raises serum calcium. Measure calcium and creatinine before starting and at one month. Women with a prior history of nephrolithiasis or hypercalcemia from any cause should be evaluated carefully before starting. The label does not absolutely contraindicate prior kidney stones, but it flags the risk.

The Osteosarcoma Black Box Warning

Like teriparatide, Tymlos carries a boxed warning about osteosarcoma risk based on rat studies showing dose- and duration-dependent osteosarcomas at exposures substantially higher than human therapeutic levels. No causal link between abaloparatide and osteosarcoma in humans has been established, and a mandatory 15-year osteosarcoma surveillance study (TOWER) is ongoing as a post-market commitment. The risk in humans is considered theoretical rather than demonstrated, but it drives the lifetime 2-year cap on anabolic therapy and the contraindication in patients with Paget's disease, prior radiation to the skeleton, or unexplained elevated alkaline phosphatase.

Atrial Fibrillation Signal

The ACTIVE trial recorded atrial fibrillation in 1.7% of abaloparatide participants versus 0.7% of placebo participants. The absolute difference is small, but it is enough that the 2019 label revision added language advising caution in women with existing arrhythmias. If you have a history of paroxysmal atrial fibrillation, request a cardiology consult or at minimum a baseline ECG before starting Tymlos.

Who Tymlos Is Right For (and Who It Is Not)

Strong Candidates by Life Stage

Postmenopause (standard approved population). Women older than 65 with T-score of -2.5 or below at the spine or hip, women of any age post-menopause with a prior fragility fracture, and women who have failed or cannot tolerate bisphosphonates are the clearest candidates. The Endocrine Society's 2019 clinical practice guideline on postmenopausal osteoporosis recommends anabolic therapy as first-line for women at very high fracture risk (defined as prior hip or vertebral fracture, T-score below -3.0, or FRAX 10-year major fracture probability above 30%).

Early postmenopause with rapid bone loss. Women who lose more than 5 percent of BMD in the first year or two after menopause despite adequate calcium and vitamin D intake may benefit from anabolic treatment earlier than standard thresholds suggest, though this remains off-guideline.

Women Who Should Not Use Tymlos

• Any woman who could be or plans to become pregnant.
• Women with a history of bone metastases or skeletal radiation.
• Women with Paget's disease of bone.
• Women with unexplained elevated alkaline phosphatase.
• Women with hypercalcemia at baseline.
• Children and adolescents (open growth plates).
• Women who have already used teriparatide for 2 years (the cumulative anabolic cap applies).

The PCOS Connection

Women with PCOS who used depot medroxyprogesterone acetate (DMPA) for contraception long-term, or who have hypothalamic amenorrhea due to exercise or disordered eating in the context of PCOS-related weight management, may develop reduced bone density before menopause. Abaloparatide is not approved for premenopausal osteoporosis, but this group deserves careful monitoring and early antiresorptive consideration, with referral to a metabolic bone specialist if BMD continues to decline.

Sequencing: What Comes Before and After Tymlos

Anabolic therapy is not a standalone treatment. ACTIVExtend data showed that women who completed 18 months of abaloparatide and then switched to 24 months of alendronate maintained and even increased the bone gains made during the anabolic phase. Without follow-on antiresorptive therapy, bone density gained during anabolic treatment is lost within 12 to 18 months. Your prescribing plan should include a named follow-on agent before you start your first Tymlos pen.

The 2020 American Association of Clinical Endocrinologists (AACE) guidelines support sequential therapy (anabolic then antiresorptive) as the optimal strategy for very-high-risk patients.

"Therapy with anabolic agents should be followed by antiresorptive therapy to maintain and augment the gains in BMD." This language appears in the Endocrine Society 2019 postmenopausal osteoporosis guideline and reflects the consensus across major bone health societies.

The Evidence Gap: What We Still Do Not Know About Abaloparatide in Women

The ACTIVE trial enrolled postmenopausal women aged 49 to 86, so its data apply most directly to that age bracket. Several important questions remain unanswered for women:

1. Premenopausal osteoporosis. No phase 3 trial has tested abaloparatide specifically in premenopausal women. Off-label use in this group relies on mechanistic extrapolation.
2. Women with chronic kidney disease (CKD) stage 3b and above. The ACTIVE trial excluded women with estimated GFR below 30 ml/min/1.73m². Hypercalcemia risk is amplified in CKD, and dosing guidance is thin.
3. Racial and ethnic diversity. The ACTIVE trial enrolled approximately 81 percent White participants. Fracture risk, bone geometry, and response to anabolic therapy differ across ethnic groups. Extrapolating ACTIVE efficacy data to Black, Hispanic, and Asian women requires caution, as the Bone Health and Osteoporosis Foundation notes in its 2022 clinical practice guide.
4. Interaction with menopausal hormone therapy (MHT). Many postmenopausal women on Tymlos also use estrogen-containing MHT. No adequately powered randomized trial has examined whether combining MHT with abaloparatide produces additive or synergistic BMD gains compared to either alone. Small pharmacokinetic studies show no significant interaction at the drug level, but fracture outcome data for the combination do not exist.

"Evidence is lacking on optimal treatment sequences in women with very high fracture risk who are also on hormone therapy," noted a 2022 editorial in Menopause, the journal of The Menopause Society. Naming that gap is not a weakness in your care plan. It is a signal that you should have a candid conversation with your clinician about what the evidence actually supports versus what is extrapolated.

Practical Guidance: Starting Tymlos in Real Life

Before Your First Injection

• Confirm a baseline DXA scan at spine and hip.
• Get baseline serum calcium, phosphorus, creatinine, and alkaline phosphatase.
• Review your cardiac history, particularly any arrhythmia.
• Confirm your contraceptive status if there is any reproductive potential.
• Ask your prescriber which antiresorptive agent you will transition to after month 18 or 24, and make sure your insurance covers it.

Injection Technique

Tymlos comes in a prefilled multidose pen containing 30 days of medication. Inject into the periumbilical abdomen, rotating sites daily. Inject at the same time each day. Sit or lie down for 30 minutes after the first injection because orthostatic hypotension (dizziness on standing) is most common with the first few doses. Keep the pen at room temperature on injection days and refrigerate between uses.

Monitoring During Treatment

The prescribing information recommends checking serum calcium approximately one month after starting. For women with a history of hypercalcemia or nephrolithiasis, more frequent monitoring is reasonable. Repeat DXA at 12 months to confirm response. If BMD has not increased by at least 3 percent at the lumbar spine by 12 months, review adherence and calcium and vitamin D intake before concluding the drug is not working.

A daily calcium intake of 1,200 mg (from food and supplements combined) and vitamin D of 800 to 1,000 IU daily is recommended throughout treatment and beyond, per ACOG's osteoporosis practice bulletin.